Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Retained Earnings (2016 - 2023)

Rapid Therapeutic Science Laboratories' Retained Earnings history spans 8 years, with the latest figure at -$10.1 million for Q2 2023.

  • For Q2 2023, Retained Earnings rose 0.59% year-over-year to -$10.1 million; the TTM value through Jun 2023 reached -$10.1 million, up 0.59%, while the annual FY2022 figure was -$10.3 million, 21.06% down from the prior year.
  • Retained Earnings for Q2 2023 was -$10.1 million at Rapid Therapeutic Science Laboratories, roughly flat from -$10.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$3.0 million in Q1 2019 and bottomed at -$10.4 million in Q3 2022.
  • The 5-year median for Retained Earnings is -$6.5 million (2021), against an average of -$6.7 million.
  • The largest annual shift saw Retained Earnings plummeted 71.83% in 2020 before it rose 0.59% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$3.3 million in 2019, then tumbled by 71.83% to -$5.7 million in 2020, then plummeted by 50.73% to -$8.5 million in 2021, then decreased by 21.06% to -$10.3 million in 2022, then increased by 2.3% to -$10.1 million in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Retained Earnings are -$10.1 million (Q2 2023), -$10.1 million (Q1 2023), and -$10.3 million (Q4 2022).